Fig. 1: NG2 glia activation in prion disease models.
a,b, Western blots (a) and quantification (b) of NG2 and NeuN in Tga20 COCS exposed to prions or NBH; n = 6 samples per condition. Data are presented as mean ± s.e.m. Unpaired t-test (two-sided): P < 0.0001 for NeuN; P = 0.0021 for NG2. c,d, Western blots (c) and quantification (d) of NG2 and Pdgfrα in brain tissues of mice inoculated with prions or NBH; n = 6 mice per condition. Data are presented as mean ± s.e.m. Unpaired t-test (two-sided): P = 0.0202 for Pdgfrα; P < 0.0001 for NG2. e, NG2 immunofluorescence showing NG2 glia activation in prion-infected Tga20 COCS versus Tga20 COCS exposed to NBH. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) (blue). f, Quantification of NG2 immunointensity shown in e; n = 12 slices for NBH; n = 14 slices for prion. Data are presented as mean ± s.e.m. Unpaired t-test (two-sided): P < 0.0001. g, NG2 glia activation in the cerebral cortex (Ctx), hippocampus (Hipp) and thalamus (Thal) of prion-inoculated mice versus mice inoculated with NBH. h, Quantification of NG2 immunointensity shown in g; n = 6 mice per group. Data are presented as mean ± s.e.m. Unpaired t-test (two-sided): P < 0.0001 for Ctx; P = 0.0001 for Hipp; P = 0.0005 for Thal.
